Compare Keysight Technologies Inc (KEYS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs GeneDx Holdings Corp — how do they compare? Keysight Technologies Inc trades at $380.76 (market cap $63.79B), while GeneDx Holdings Corp trades at $67.77 (market cap $2.02B). The key difference: Keysight Technologies Inc is far larger — about 31.6× GeneDx Holdings Corp's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and GeneDx Holdings Corp for 19 Days on average.
| KEYS | WGS | |
|---|---|---|
Market Cap | $63.79B | $2.02B |
Volume | 1,435,384 | 734,640 |
Sector | Technology | Health |
52-Week High | $387.90 | $167.51 |
52-Week Low | $159.49 | $34.51 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $63.93B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.75, up 0.33% with strong technical momentum as it approaches resistance at $385. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.07 versus $2.48, supported by 19.14% net margins and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, with orders surging 56% in Q3 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and $416.63 consensus target, though elevated P/E of 50.7 presents valuation risk. Growth catalysts include AI data-center expansion and 6G wireless development, while risks involve supply constraints and competitive pressures in the testing equipment market.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
